Goran Toncev1. 1. Clinical Center Kragujevac, Center of Neurology, Kragujevac, Srbija.
Abstract
BACKGROUND/AIM: Uric acid was successfully used in both, prevention and treatment of the animal model of multiple sclerosis (MS). Recently it has been shown that inosine, a ribosylated precursor of uric acid, might be used to elevate serum uric acid levels in MS patients. The aim of this study was to evaluate the safety and efficacy of oral inosine as a single drug treatment in patients with MS. METHOD: We administered inosine orally to 32 MS patients from 2001-2004 year at doses from 1-2 g daily (given twice) depending on the pretreatment serum uric acid levels. The mean follow-up interval was 37.69+/-6.55 months. The other 32 MS patients, without any treatment except for a relapse period (matched by age, sex, duration of disease and functional disability), were used as controls. The follow-up interval of these patients was 36.39 +/- 2.68 months. The neurological disability was evaluated by the Expanded Disability Status Scale score (EDSS). RESULTS: During the observed period the treated MS patients were found to have the lower relapses rate than the non-treated MS patients (Chi-square test, p = 0.001). None of the patients have showed any adverse effect of inosine treatment. The non-treated MS patients were found to have a higher increasing in the mean EDSS score than the treated ones (two-way ANOVA-repeated measures/factor times, p = 0.025). CONCLUSION: Our results suggested that the treatment approaches based on the elevation of serum uric acid levels might prove beneficial for some MS patients.
BACKGROUND/AIM: Uric acid was successfully used in both, prevention and treatment of the animal model of multiple sclerosis (MS). Recently it has been shown that inosine, a ribosylated precursor of uric acid, might be used to elevate serum uric acid levels in MSpatients. The aim of this study was to evaluate the safety and efficacy of oral inosine as a single drug treatment in patients with MS. METHOD: We administered inosine orally to 32 MSpatients from 2001-2004 year at doses from 1-2 g daily (given twice) depending on the pretreatment serum uric acid levels. The mean follow-up interval was 37.69+/-6.55 months. The other 32 MSpatients, without any treatment except for a relapse period (matched by age, sex, duration of disease and functional disability), were used as controls. The follow-up interval of these patients was 36.39 +/- 2.68 months. The neurological disability was evaluated by the Expanded Disability Status Scale score (EDSS). RESULTS: During the observed period the treated MSpatients were found to have the lower relapses rate than the non-treated MSpatients (Chi-square test, p = 0.001). None of the patients have showed any adverse effect of inosine treatment. The non-treated MSpatients were found to have a higher increasing in the mean EDSS score than the treated ones (two-way ANOVA-repeated measures/factor times, p = 0.025). CONCLUSION: Our results suggested that the treatment approaches based on the elevation of serum uric acid levels might prove beneficial for some MSpatients.
Authors: Roy G Cutler; Simonetta Camandola; Kelli F Malott; Maria A Edelhauser; Mark P Mattson Journal: Curr Top Med Chem Date: 2015 Impact factor: 3.295
Authors: Stella Célio Junqueira; Igor Dos Santos Coelho; Vicente Lieberknecht; Mauricio Peña Cunha; João B Calixto; Ana Lúcia S Rodrigues; Adair Roberto Soares Santos; Rafael Cypriano Dutra Journal: Mol Neurobiol Date: 2016-04-30 Impact factor: 5.590
Authors: Michael A Schwarzschild; Alberto Ascherio; M Flint Beal; Merit E Cudkowicz; Gary C Curhan; Joshua M Hare; D Craig Hooper; Karl D Kieburtz; Eric A Macklin; David Oakes; Alice Rudolph; Ira Shoulson; Marsha K Tennis; Alberto J Espay; Maureen Gartner; Albert Hung; Grace Bwala; Richard Lenehan; Elmyra Encarnacion; Melissa Ainslie; Richard Castillo; Daniel Togasaki; Gina Barles; Joseph H Friedman; Lisa Niles; Julie H Carter; Megan Murray; Christopher G Goetz; Jeana Jaglin; Anwar Ahmed; David S Russell; Candace Cotto; John L Goudreau; Doozie Russell; Sotirios Andreas Parashos; Patricia Ede; Marie H Saint-Hilaire; Cathi-Ann Thomas; Raymond James; Mark A Stacy; Julia Johnson; Lisa Gauger; J Antonelle de Marcaida; Sheila Thurlow; Stuart H Isaacson; Lisbeth Carvajal; Jayaraman Rao; Maureen Cook; Charlise Hope-Porche; Lauren McClurg; Daniela L Grasso; Robert Logan; Constance Orme; Tori Ross; Alicia F D Brocht; Radu Constantinescu; Saloni Sharma; Charles Venuto; Joseph Weber; Ken Eaton Journal: JAMA Neurol Date: 2014-02 Impact factor: 18.302
Authors: Clyde E Markowitz; Sergei Spitsin; Vanessa Zimmerman; Dina Jacobs; Jayaram K Udupa; D Craig Hooper; Hilary Koprowski Journal: J Altern Complement Med Date: 2009-06 Impact factor: 2.579